一種新型不透輻射的骨骼粘合劑叫做Symphony VR，被研制在脊椎椎體填充術或者椎體后凸成形術的時候，用于脊椎骨病理性骨折的固定。這種骨骼粘合劑已經獲得了美國食品藥品管理局的許可。

令人疼痛難忍的脊椎壓縮性骨折可能是由于骨質疏松、良性病變（血管瘤）、轉移性癌比如骨髓瘤而導致的后果。與使用其它單體產品相比較，這種粘合劑先與不透輻射物質預先混和，使得脊柱醫生操作時間更長，操作過程中產熱更少。骨骼空腔充填系統叫做Plexis使用獲得的混和與輸送工藝，保證了外科醫生最大程度地控制手術。Symphony VR是ABS公司的產品。

ABS公司總裁兼首席執行官Pete Carr指出：“FDA的許可允許ABS向市場將Plexis混和與輸送系統以及ABS的Symphony VR不透輻射的骨骼粘合劑做為整體推廣。在脊椎椎體填充術或者椎體后凸成形術的時候，為脊柱醫生提供了脊椎壓縮性骨折的固定提供了解決方案。”

Radiopaque Bone Cement for Fracture Fixation
 
A new radiopaque bone cement called Symphony VR has been developed for use in the fixation of pathologic fractures of the vertebral body using vertebroplasty or kyphoplasty procedures. The bone cement has been cleared by the U.S. Food and Drug Administration (FDA).

Painful vertebral compression fractures can result from osteoporosis, benign lesions (hemangioma), and metastatic cancers such as myeloma. The cement comes premixed with a radiopacifier, giving a spine doctor longer working time and a lower exothermic temperature while using less monomer than other products. A bone-void filling system called Plexis utilizes a patented mixing and delivery technology that gives the surgeon maximum control. Symphony VR is the product of Advanced Biomaterial Systems, Inc. (ABS, Chatam, NJ, USA; www.advbiomat.com).

“This FDA clearance now allows ABS to market its Plexis mixing and delivery system together with ABS’s Symphony VR radiopaque bone cement as a complete and controlled solution to spine physicians for stabilizing spinal compression fractures for use in either vertebroplasty or kyphoplasty procedures,” noted Pete Carr, president and CEO of ABS.